PHARMACOGENOMICS OF MDR1 IN PATIENTS WITH CYSTIC FIBROSIS (CF)

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。囊性纤维化患者对一些化合物的肾脏清除率似乎有所增加。体外和动物实验数据表明，肾小管内p -糖蛋白的上调可能是该人群中囊性纤维化跨膜调节基因（CFTR）缺陷的代偿机制。本研究的目的是比较P-gp探针非索非那定在CF患者和年龄匹配的对照组中的药代动力学。此外，将评估MDR1基因型与表型的关系。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The renal clearance of a number of compounds appears to be increased in patients with cystic fibrosis. In-vitro and animal data indicate that upregulation of P-glycoprotein within the renal tubules may account for the increased clearance in this population as a compensatory mechanism for the defect in the cystic fibrosis transmembrane regulatory gene (CFTR). The purpose of this study is to compare the pharmacokinetics of a P-gp probe, fexofenadine in patients with CF and age-matched control subjects. In addition, MDR1 genotype-phenotype relationships will be evaluated.